Currently Viewing:
Newsroom
Currently Reading
Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval
May 14, 2018 – Jaime Rosenberg
CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
May 09, 2018 – Samantha DiGrande
This Week in Managed Care: May 4, 2018
May 04, 2018
AJMC® in the Press, May 4, 2018
May 04, 2018 – AJMC Staff
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 02, 2018 – Jaime Rosenberg
What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits
May 02, 2018 – AJMC Staff
FDA, FTC Warn 13 Firms for Selling Vaping Juice With Kid-Friendly Appeal
May 01, 2018 – Allison Inserro
FDA Grants Priority Review for Pembrolizumab, Chemotherapy Combination in NSCLC
April 30, 2018 – Jaime Rosenberg
Researchers Identify New Gene That Predisposes People to ALL
April 30, 2018 – Laura Joszt

Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval

Jaime Rosenberg
In the 4 months following their approvals, pembrolizumab and nivolumab reached more than 60% of eligible patients with melanoma, non-small cell lung cancer, and renal cell carcinoma.
Following their approval, anti–PD-1 agents reach a significant proportion of patients within a few months, according to new study findings.

Anticancer agents, including anti–PD-1 agents, continue to enter the market at an accelerated rate through the breakthrough designation. While traditional estimates  suggest it often takes more than 10 years for innoations to change patient care, little is known about how quickly novel therapies reach the hands of patients. 

To answer this question, researchers conducted a retrospective cohort study of patients receiving nivolumab or pembrolizumab for previously treated or untreated melanoma, nivolumab or pembrolizumab for previously treated non–small cell lung cancer (NSCLC), or nivolumab for previously treated renal cell carcinoma (RCC) from January 1, 2011 through August 31, 2016. The results were published in JAMA Oncology.

Of the 3089 patients eligible for anti–PD-1 treatment, 555 had melanoma, 2159 had NSCLC, and 375 had RCC. The median age at diagnosis of advanced stage disease for patients with melanoma and RCC was 66 and for patients with NSCLC was 67.

More than 60% of patients in each cohort received anti–PD-1 treatment within 4 months of the FDA approval. By the end of the study period, 439 patients with melanoma (79.1%), 1417 patients with NSCLC (65.6%), and 267 patients with RCC (71.2%) had received anti–PD-1 treatment.

The authors observed rapid uptake of pembrolizumab for melanoma in the first 3 months following FDA approval, with 31 of 44 patients receiving the treatment. However, in the following 12 months, nivolumab became the preferred anti–PD-1 treatment for melanoma. In NSCLC, there was rapid uptake of nivolumab, but not pembrolizumab.

“Such rapid adoption stands in contrast to older estimates that suggest it takes years or even decades for new treatments to be adopted, including evidence that highly effective treatments, such as tamoxifen for breast cancer, can take more than 10 years to reach most eligible patients,” wrote the authors.

The swift uptake of these treatments may be attributable to high disease severity, overall preference for novelty, perceived gains over existing treatments, and promotional activities, such as direct to consumer advertisements, they explained.

Of note, there were larger proportions of patients treated with anti–PD-1 drugs aged 65 and older in real-world cohorts than in pivotal trials. However, with up to 9 months of followup, the uptake of each treatment was similar among younger and older patients, which suggests that patient age is unlikely to be associated with differences in clinical adoption of the treatments, according to the authors.

Reference:

O'Connor J, Fessele K, Steiner J, et al. Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials. JAMA Oncol. doi:10.1001/jamaoncol.2018.0798.

Related Articles

Knowing Which RCC Patients Do Not Qualify for Nivolumab Treatment
Report: Immune Checkpoint Proteins Are the Focus of Cancer Immunotherapy Development
Checkpoint Inhibitors Associated With Prolonged Survival in NSCLC
Participating Faculty - The Role of Immuno-Onc in Treatment Advanced Melanoma
Oncologists Must Weigh Risks, Benefits of Immune Checkpoint Inhibitors
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up